Skip to search formSkip to main contentSkip to account menu

LY 186641

Known as: LY-186641, LY186641 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

sulofenur

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2004
2004
Evaluation of N-(5-indanylsulfonyl)-N′-(4-chlorophenyl)-urea against xenografts of pediatric rhabdomyosarcoma
SummaryN-(5-indanylsulfonyl)-N′-(4-chlorophenyl)-urea (LY186641), a novel anticancer compound, was evaluated against six lines of… 
2004
2004
Evaluation of the methemoglobinemia associated with Sulofenur
SummaryA new class of antineoplastic agents, the diarylsulfonylureas entered clinical trials with the testing of Sulofenur… 
1994
1994
Phase I trial of sulofenur (LY186641) given orally on a daily x 21 schedule.
Sulofenur (LY186641), a diarylsulfonylurea, was evaluated clinically utilizing either a daily x 21 schedule or a daily x 5 (with… 
1993
1993
Effect of albumin on antitumor activity of diarylsulfonylureas.
Several diarylsulfonylureas (DSU), including Sulofenur (LY186641) and LY181984, have been described that exhibit wide spectrum… 
1993
1993
Pharmacokinetics of the anticancer agent sulofenur in mice, rats, monkeys, and dogs.
The absorption and pharmacokinetics of sulofenur [N-(indan-5-sulfonyl)-N'-(4-chlorophenyl)urea, LY186641] and its major… 
1992
1992
A phase II study of sulofenur (LY186641) in gastric cancer
Sulofenur is a novel diarylsulfonylurea with proven antitumor activity in murine tumor models. In this phase II study in patients… 
1991
1991
Phase II study of sulofenur (LY186641) in untreated patients with extensive small cell lung cancer.
1990
1990
Kinetics of N-[(4-chlorophenyl)amino]carbonyl-2,3-dihydro-1H-indene-5-sulfonamide (LY186641) in humans.
The metabolism and disposition of LY186641, a diarylsulfonylurea with antineoplastic activity identified in preclinical tests… 
1989
1989
Phase I clinical study of N-[(4-chlorophenyl)amino]carbonyl-2,3-dihydro-1H-indene-5-sulfonamide (LY186641).
Between February 1987 and July 1988, 45 patients with advanced refractory cancer were treated with LY186641, a diarylsulfonylurea… 
1989
1989
Clinical pharmacology of a novel diarylsulfonylurea anticancer agent.
LY186641 (diarylsulfonylurea, [DSU]) is a novel anticancer agent because of its unique diarylsulfonylurea chemical structure… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)